Huadong Medicine

Company Deals

Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million

Fineline Cube Aug 11, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review

Fineline Cube Jul 14, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Company Drug

Huadong Medicine’s SaiYueXin Receives NMPA Approval for Pediatric Psoriasis Treatment

Fineline Cube Mar 4, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link